Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BackgroundEpisodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy.ObjectiveTo determine whether reinitiating continuous antiretroviral therapy in patients who received episodic treatment reduces excess risk for opportunistic disease or death.DesignRandomized, controlled trial.SettingSites in 33 countries.Patients5472 HIV-infected individuals with CD4(+) cell counts greater than 0.350 x 10(9) cells/L enrolled from January 2002 to January 2006.InterventionEpisodic or continuous antiretroviral therapy initially, followed by continuous therapy in participants previously assigned to episodic treatment.MeasurementsOpportunistic disease or death was the primary outcome.ResultsEighteen months after the recommendation to reinitiate continuous therapy, mean CD4+ cell counts were 0.152 x 10(9) cells/L (95% CI, 0.136 to 0.167 x 10(9) cells/L) less in participants previously assigned to episodic treatment (P < 0.001). The proportion of follow-up time spent with CD4+ cell counts of 0.500 x 10(9) cells/L or more and HIV RNA levels of 400 copies/mL or less was 29% for participants initially assigned to episodic therapy and 66% for those assigned to continuous therapy. Participants who reinitiated continuous therapy experienced rapid suppression of HIV RNA levels (89.7% with HIV RNA levels < or =400 copies/mL after 6 months), but CD4+ cell counts after 6 months remained 0.140 x 10(9) cells/L below baseline. The hazard ratio (episodic versus continuous treatment) for opportunistic disease or death decreased after the recommendation to reinitiate continuous therapy (from 2.5 [CI, 1.8 to 3.5] to 1.4 [CI, 1.0 to 2.0]; P = 0.033 for difference). The residual excess risk was attributable to failure to reinitiate therapy by some participants and slow recovery of CD4+ cell counts for those who reinitiated therapy.LimitationFollow-up was too short to assess the full effect of switching from episodic to continuous antiretroviral therapy.ConclusionReinitiating continuous antiretroviral therapy in patients previously assigned to episodic treatment reduced excess risk for opportunistic disease or death, but excess risk remained. Episodic antiretroviral therapy, as used in the SMART study, should be avoided.

Original publication




Journal article


Annals of internal medicine

Publication Date





289 - 299


SMART Study Group, Humans, HIV, AIDS-Related Opportunistic Infections, HIV Infections, RNA, Viral, Anti-HIV Agents, CD4 Lymphocyte Count, Viral Load, Drug Administration Schedule, Risk Factors, Follow-Up Studies, Kaplan-Meier Estimate